Skip to content

The efficacy and safety of SGLT2 inhibitors on patients with type 2 diabetes mellitus combined with chronic kidney disease

The efficacy and safety of of SGLT2 inhibitors on patients with type 2 diabetes mellitus combined with chronic kidney disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072845
Enrollment
Unknown
Registered
2023-06-26
Start date
2023-01-10
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus and chronic kidney disease

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Meeting the American Diabetes Association's diagnostic criteria for type 2 diabetes mellitus 2) Clinical diagnosis of chronic kidney disease: the following renal structural or functional abnormalities persist > 3 months ? eGFR < 60ml/min/1.73m2 or ? abnormal urine protein such as proteinuria 1+ or random urine albumin/creatinine ratio (UACR) = 30mg/g or ? histology or imaging showing renal abnormalities. 3) The following inclusion criteria were also met: (i) age 18-70 years; (ii) have been using basic treatment for more than three months, antihypertensive drugs such as ARB, other non-SGLT2i hypoglycemic drugs, statin lipid-lowering drugs, etc.; (iii) Patients who were initially treated with SGLT2i and tested for body composition analysis, while at the same time, the patient was tested again for body composition at 6 months of treatment with SGLT2i

Exclusion criteria

Exclusion criteria: 1) Entering end-stage renal disease (eGFR <15ml/min/1.73m2 or on renal replacement therapy) 2) Patients with malignancy, cirrhosis or severe infection 3) Pregnant or breastfeeding patients 4) Patients treated with glucocorticoids

Design outcomes

Primary

MeasureTime frame
body composition ;Glomerular filtration rate;Blood lipids;urinary albumin creatinine ratio;Glycated hemoglobin;

Secondary

MeasureTime frame
Routine blood tests;

Countries

China

Contacts

Public ContactFang Liu

Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China

liufangfh@163.com+86 189 8060 1214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026